As he approaches his 18th signature shoe, there haven’t been many misses when it comes to design—KD has definitely been on point. Most fans of his line would probably say the KD 6s and 7s are ...

The Nike KD 18 "Soft Pearl" has arrived, and while the color is a softer tone, the silhouette is one that presents strength. Due out on May 1, the shoe arrives dressed in cream-toned upper ...

Among the most significant milestones was the launch of ustekinumab biosimilars following the loss of exclusivity for Stelara. This expansion has played a pivotal role in fostering market ...

CEO Joaquin Duato cited 4.2% operational sales growth in innovative medicine, despite the negative impact from biosimilar competition for STELARA, and emphasized the company’s strong product ...

In 2024, the U.S. healthcare industry spent $6.1 billion on Pfizer’s COVID-19 therapy Paxlovid, a 6,922.8% increase from 2023 expenditure data, according to a recent study. The research ...

We've also had vedolizumab for a number of years for Crohn's disease. While we've had stelara for Crohn's, more recently, we have had medications such as risankizumab approved in the last few ...

On the one hand, sales of Tremfya [guselkumab], which is the successor to Stelara [ustekinumab], grew by 18.3% year-on-year to $956 million, and the Simponi franchise by 19% to $659 million in the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Obesity was associated with lower odds of steroid-free clinical remission in patients with inflammatory bowel disease (IBD) at week 24 after the initiation of treatment. "In clinical practice, it ...

assets in Tremfya and Stelara. JNJ's orally available Icotrokinra recently aced a Phase 3 study in plaque psoriasis, but the way AbbVie tells, it, this is unlikely to impact the growth of Skyrizi.

J&J has said it will now need upfront payment in full for its anticoagulant Xarelto (rivaroxaban) and immunology therapy Stelara (ustekinumab), with a rebate paid later, rather than the previous ...

There is heavyweight competition in the biologics category from the likes of Johnson & Johnson's IL-23 inhibitor Stelara (ustekinumab) as well as AbbVie's TNF inhibitor Humira (adalimumab ...